NY-ESO-1 TCR单基因编辑干记忆与中央记忆T细胞治疗多发性骨髓瘤且不引发移植物抗宿主病
研究开发基于仅敲除内源性TCRα链的TCR「单编辑」(SE)技术,并用临床级HLA-A2限制性NY-ESO-1 157-165特异性TCR验证。SE可快速制备高数量肿瘤特异性T细胞,优先呈现干记忆与中央记忆表型,高效杀伤NY-ESO-1阳性靶细胞;与常规TCR基因转移(TR)细胞不同,SE细胞在NSG小鼠骨髓瘤模型中介导肿瘤排斥且不诱发异种移植物抗宿主病,生存期显著优于TR细胞组。
要点
- SE仅敲除内源性TCRα链后导入肿瘤特异性TCR,较完全编辑减少操作与转导步骤。
- SE细胞优先呈现干记忆与中央记忆表型,高效杀伤NY-ESO-1阳性靶细胞。
- NSG小鼠骨髓瘤模型中SE细胞介导肿瘤排斥且无异种GVHD,生存期高于TR细胞组。
核心结论
- 单TCR基因编辑是临床可行的策略,能够提高肿瘤过继免疫治疗的安全性与疗效。
研究设计与样本
- 临床前研究:开发基于敲除内源性TCRα链的TCR单编辑(SE)技术,并以临床级HLA-A2限制性NY-ESO-1 157-165特异性TCR进行验证。
- 在NSG小鼠骨髓瘤模型中比较SE细胞与常规TCR基因转移(TR)细胞的体内效果。
主要发现
- SE可快速制备高数量肿瘤特异性T细胞,TCR表达最佳,并优先呈现干记忆与中央记忆表型。
- SE细胞与TR细胞均高效杀伤NY-ESO-1阳性靶细胞,但TR细胞高度同种反应性,SE细胞显示良好安全性。
- NSG小鼠骨髓瘤模型中,SE细胞介导肿瘤排斥且不诱导异种移植物抗宿主病,生存期显著高于TR细胞治疗小鼠。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transfer of T-cell receptors (TCRs) specific for tumor-associated antigens is a promising approach for cancer immunotherapy. We developed the TCR gene editing technology that is based on the knockout of the endogenous TCR α and β genes, followed by the introduction of tumor-specific TCR genes, and that proved safer and more effective than conventional TCR gene transfer. Although successful, complete editing requires extensive cell manipulation and 4 transduction procedures. Here we propose a novel and clinically feasible TCR "single editing" (SE) approach, based on the disruption of the endogenous TCR α chain only, followed by the transfer of genes encoding for a tumor-specific TCR. We validated SE with the clinical grade HLA-A2 restricted NY-ESO-1157-165-specific TCR. SE allowed the rapid production of high numbers of tumor-specific T cells, with optimal TCR expression and preferential stem memory and central memory phenotype. Similarly to unedited T cells redirected by TCR gene transfer (TCR transferred [TR]), SE T cells efficiently killed NY-ESO-1pos targets; however, although TR cells proved highly alloreactive, SE cells showed a favorable safety profile. Accordingly, when infused in NSG mice previously engrafted with myeloma, SE cells mediated tumor rejection without inducing xenogeneic graft-versus-host disease, thus resulting in significantly higher survival than that observed in mice treated with TR cells. Overall, single TCR gene editing represents a clinically feasible approach that is able to increase the safety and efficacy of cancer adoptive immunotherapy.
引用
- Mastaglio S, Genovese P, Magnani Z, et al. NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. Blood. 2017. PMID: 28637663. doi:10.1182/blood-2016-08-732636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。